JP Morgan Initiates Coverage On Alamar Biosciences with Overweight Rating, Announces Price Target of $30

Benzinga Newsdesk www.benzinga.com Neutral 56.8%

Neg 0% Neu 56.8% Pos 0%

JP Morgan analyst Casey Woodring initiates coverage on Alamar Biosciences (NASDAQ:ALMR) with a Overweight rating and announces Price Target of $30.